The global autotransfusion devices market size 2026 was valued at USD 329.61 million in 2025 and is projected to grow from USD 350.97 million in 2026 to USD 590.49 million by 2034, exhibiting a steady CAGR of 6.72% over the forecast period. Autotransfusion — also known as cell saver technology — enables patients to use their own blood during surgical procedures, offering a safer alternative to donor blood transfusions. These devices eliminate the need for cross-matching, reduce the risk of transfusion reactions and infection, and are used across cardiovascular, orthopedic, neurological, and obstetric & gynecological surgeries.
Key Market Drivers
The rising number of surgical procedures for chronic conditions — including cardiac and neurological disorders — is a primary force behind market expansion. The growing volume of organ transplants further accelerates demand. According to the U.S. Health Resources and Services Administration (HRSA), 46,632 organ transplants were performed in the U.S. in 2023 alone, a near 8.7% increase over 2022.
An expanding geriatric population, increasingly susceptible to chronic diseases requiring major surgery, creates sustained demand for advanced blood management systems. Additionally, a persistent global gap between blood supply and demand — especially in emerging markets — presents significant growth opportunity. In China, for instance, while blood supply grew approximately 7% over a decade, surgical procedures rose by 18%, creating a notable shortfall that autotransfusion technologies are well-positioned to address.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/autotransfusion-devices-market-101899
Market Restraints & Challenges
The growing patient preference for minimally invasive surgeries poses a restraint on market growth, as these procedures involve minimal blood loss and reduce the need for blood conservation techniques. Furthermore, rising development of advanced hemostatic devices presents competitive pressure.
The high cost of autotransfusion systems is another key challenge, particularly for adoption in emerging economies with limited healthcare budgets. The risk of infection in contaminated surgical environments also limits device usage across all patient and surgery types.
Segmentation Highlights
By Product Type: Consumables & Accessories dominate with an estimated 58.10% share in 2026, driven by the high volume of surgeries and the need for frequent consumable replacement. Autotransfusion systems — spanning intraoperative, post-operative, and dual-mode variants — are growing steadily due to rising awareness of autologous blood transfusion benefits.
By Application: The cardiovascular surgeries segment leads with a 60.11% market share in 2024, reflecting high usage in procedures such as CABG, heart transplantation, and valve replacement. Orthopedic surgeries hold the second-highest share, while neurological and obstetric segments are growing at a moderate pace.
By End User: Hospitals dominate with approximately 89.67% share in 2026, driven by the concentration of major surgeries in hospital settings. Specialty clinics are growing steadily, particularly in developed markets.
Regional Outlook
North America leads the global market at 49.76% share (USD 164.03 million in 2025), underpinned by advanced healthcare infrastructure, established autotransfusion guidelines from bodies like the American Association of Blood Banks, and a high volume of cardiovascular and orthopedic procedures.
Europe contributed 34.88% (USD 114.97 million in 2025), with strong performance in Germany, the UK, and France, supported by growing provider awareness and increasing surgical volumes.
Asia Pacific accounted for 10.94% (USD 36.05 million in 2025). Growth is driven by expanding hospital networks — China alone had over 12,649 primary hospitals and 36,100 community health centers as of 2021 — and rising adoption of cell salvage technologies across the region.
Competitive Landscape
The market is highly consolidated. LivaNova Plc, Haemonetics Corporation, and Fresenius SE & Co. KGaA are the dominant players, accounting for a significant collective market share. Key developments include Haemonetics receiving FDA 510(k) clearance in March 2023 for next-generation software for its Cell Saver Elite+ Autotransfusion System, and Atlanpole Biotherapies receiving CE approval in September 2022 for its i-SEP device, capable of recovering both red blood cells and platelets during bleeding procedures. Other active players include Medtronic, BD, Beijing Jingjing Medical Equipment Co., Ltd., and ProCell Surgical Inc.
Conclusion
The autotransfusion devices market is on a strong growth trajectory through 2034, driven by increasing surgical volumes, an aging global population, technological innovation, and the persistent need for safer blood management alternatives. While cost barriers and the rise of minimally invasive procedures present headwinds, the ongoing gap between blood supply and surgical demand ensures robust long-term opportunity across both developed and emerging markets.